<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest update is out from Inotiv ( (NOTV) ). On April 20, 2026, Inotiv, Inc. disclosed that lenders under its November 5, 2021 Credit Agreement granted a waiver of the minimum liquidity covenant for the April 17 and April 24, 2026 liquidity test dates. The waiver is narrowly tailored to those specific dates and covenant requirements, leaving all other terms of the Credit Agreement unchanged, which suggests short-term liquidity pressure but preserves the broader financing structure and lender relationship. By limiting the waiver to the minimum liquidity covenant and to defined test dates, Inotiv and its lenders avoided a broader amendment of the credit facility that could signal more extensive restructuring. This targeted accommodation may ease immediate compliance concerns while maintaining the integrity of the existing debt terms, a trade-off closely watched by creditors and investors assessing the company’s short-term financial flexibility. The most recent analyst rating on (NOTV) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Inotiv stock, see the NOTV Stock Forecast page. Spark’s Take on NOTV Stock According to Spark, TipRanks’ AI Analyst, NOTV is a Neutral. The score is held down primarily by weak financial quality—ongoing net losses, negative operating/free cash flow, and very high leverage—despite improving revenue and positive EBITDA. The earnings call adds mixed signals: strong DSA demand indicators (awards/backlog) are offset by declining cash, lack of formal guidance, RMS volume pressure, and refinancing/covenant risk. Technically, the stock shows only a short-term bounce while remaining in a broader downtrend; valuation appears optically low due to losses and offers no dividend support. To see Spark’s full report on NOTV stock, click here. More about Inotiv Inotiv, Inc. operates in the life sciences and research services industry, providing preclinical and analytical services to pharmaceutical, biotechnology, and related clients. The company works with its subsidiaries under a syndicated credit facility to support its operations and financing needs. Average Trading Volume: 604,585 Technical Sentiment Signal: Sell Current Market Cap: $13.4M See more data about NOTV stock on TipRanks’ Stock Analysis page.</div>

NOTV

Inotiv, Inc. has received a targeted waiver from lenders regarding its minimum liquidity covenant for specific test dates in April 2026, indicating short-term liquidity pressure while maintaining the overall credit agreement. This waiver avoids broader amendments that could imply extensive restructuring. Analysts rate Inotiv's stock (NOTV) as a Buy with a $1.50 price target, though concerns about financial quality persist, including ongoing losses and high leverage. The company operates in life sciences, providing preclinical and analytical services.

Inotiv Receives Targeted Waiver on Liquidity Covenant Tests